Mocravimod hydrochloride

Cat. No.: HY-13660

CAS No.: 509088-69-1

Molecular Formula: $C_{24}H_{27}Cl_2NO_3S$

Molecular Weight: 480.45

Target: LPL Receptor

Pathway: GPCR/G Protein

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (416.28 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.0814 mL	10.4069 mL	20.8138 mL
	5 mM	0.4163 mL	2.0814 mL	4.1628 mL
	10 mM	0.2081 mL	1.0407 mL	2.0814 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.20 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (5.20 mM); Suspended solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (5.20 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Mocravimod hydrochloride (KRP-203), an immunosuppressant, is a potent and orally active S1PR1 (sphingosine 1-phosphate receptor type 1) agonist[1][2].

IC_{50} & Target

S1PR1[1]

In Vivo

Mocravimod hydrochloride (KRP-203) ameliorates atherosclerosis in LDL-R / Mice[1].

Mocravimod hydrochloride (KRP-203) (orally; 0.1 and 1 mg/kg/day; for 100 days) prolongs graft survival and attenuates chronic rejection in mHC-disparate rat heart allografts[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Inbred male DA (MHC haplotype: $RT1^a$) rats[2]
Dosage:	0.1 and 1 mg/kg
Administration:	Orally; daily; for 100 days
Result:	Prolonged graft survival and attenuated chronic rejection in mHC-disparate rat heart allografts.

REFERENCES

[1]. Potì F, et al. KRP-203, sphingosine 1-phosphate receptor type 1 agonist, ameliorates atherosclerosis in LDL-$R^{-/-}$ mice. Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1505-12.

[2]. Shimizu H, et al. KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronicrejection in rat skin and heart allografts. Circulation. 2005 Jan 18;111(2):222-9. Epub 2005 Jan 10.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA